An Anti-Human ICAM-1 Antibody Inhibits Rhinovirus-Induced Exacerbations of Lung Inflammation
Figure 7
Effect of topically dosed 14C11 antibody on HRV16 induced exacerbation of allergic airway inflammation in vivo.
Groups of 8 transgenic positive mice were OVA sensitised on day −13 and re-challenged either with PBS or OVA on day −2 and day −1. On day 0 mice were dosed intranasally with 14C11 or isotype control 2 hours prior to intranasal challenge with PBS or OVA and infected HRV16 (RV-PBS and RV-OVA) or UV-inactivated HRV16 (UV-PBS or UV-OVA). (A) Total BAL cells, neutrophil and macrophage numbers were assessed on day 2 after infection and (B) lymphocyte and eosinophil numbers on day 6 after infection. (C) Airway hyper-responsiveness was determined on day 1 after infection. The levels of cytokines and chemokines (D) IL-4, IL-5, IL-13, IL-6 and CXCL1 in BAL and CXCL11 in lung homogenate 2 days after infection. (E) Total IgE in serum and levels of MUC5AC and MUC5B protein in BAL on day 6 after infection. Significance was assessed by One-way ANOVA test with Bonferroni's Multiple Comparison test as post-test. *p<0.05, **p<0.01 and ***p<0.001 vs transgenic positive mice pretreated with isotype control and challenged with RV-OVA. Data are representative of 3 independent experiments.